Request Free Sample ×
Italy Fertility Drug Surgery Market Research Report-Forecast to 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Italy Fertility Drug Surgery Market

ID: MRFR/Pharma/52252-HCR
200 Pages
Vikita Thakur
Last Updated: April 06, 2026

Italy Fertility Drug Surgery Market Research Report By Underlying Cause (Male, Female), By Drugs (Clomiphene Citrate, Letrozole), By Procedures (Hysteroscopy, Laparoscopy, Robotic Laparoscopy) and By End User (Fertility Clinics) -Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Italy Fertility Drug Surgery Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Life Sciences, BY Underlying Cause (USD Million)
  49.     4.1.1 Male
  50.     4.1.2 Female
  51.   4.2 Life Sciences, BY Drug (USD Million)
  52.     4.2.1 Clomiphene Citrate
  53.     4.2.2 Letrozole
  54.     4.2.3 Serophene
  55.     4.2.4 Hormone Treatment
  56.     4.2.5 Gonadotrophins
  57.     4.2.6 Aromatase Inhibitors
  58.     4.2.7 Estrogen Receptor Modulators
  59.     4.2.8 Dopamine Agonists
  60.     4.2.9 Metformin Hydrochloride
  61.     4.2.10 Others
  62.   4.3 Life Sciences, BY Procedures (USD Million)
  63.     4.3.1 Hysteroscopy
  64.     4.3.2 Laparoscopy and Robotic Laparoscopy
  65.     4.3.3 Laparotomy/Open Surgery
  66.     4.3.4 Egg Retrieval
  67.     4.3.5 Varicocelectomy
  68.     4.3.6 Vasectomy Reversal
  69.     4.3.7 Sperm Retrieval
  70.   4.4 Life Sciences, BY End-User (USD Million)
  71.     4.4.1 Fertility Clinics
  72.     4.4.2 Hospitals
  73.     4.4.3 Clinical Research Institutes
  74.     4.4.4 Others
  75. 5 SECTION V: COMPETITIVE ANALYSIS
  76.   5.1 Competitive Landscape
  77.     5.1.1 Overview
  78.     5.1.2 Competitive Analysis
  79.     5.1.3 Market share Analysis
  80.     5.1.4 Major Growth Strategy in the Life Sciences
  81.     5.1.5 Competitive Benchmarking
  82.     5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  83.     5.1.7 Key developments and growth strategies
  84.       5.1.7.1 New Product Launch/Service Deployment
  85.       5.1.7.2 Merger & Acquisitions
  86.       5.1.7.3 Joint Ventures
  87.     5.1.8 Major Players Financial Matrix
  88.       5.1.8.1 Sales and Operating Income
  89.       5.1.8.2 Major Players R&D Expenditure. 2023
  90.   5.2 Company Profiles
  91.     5.2.1 Ferring Pharmaceuticals (CH)
  92.       5.2.1.1 Financial Overview
  93.       5.2.1.2 Products Offered
  94.       5.2.1.3 Key Developments
  95.       5.2.1.4 SWOT Analysis
  96.       5.2.1.5 Key Strategies
  97.     5.2.2 Merck KGaA (DE)
  98.       5.2.2.1 Financial Overview
  99.       5.2.2.2 Products Offered
  100.       5.2.2.3 Key Developments
  101.       5.2.2.4 SWOT Analysis
  102.       5.2.2.5 Key Strategies
  103.     5.2.3 Bayer AG (DE)
  104.       5.2.3.1 Financial Overview
  105.       5.2.3.2 Products Offered
  106.       5.2.3.3 Key Developments
  107.       5.2.3.4 SWOT Analysis
  108.       5.2.3.5 Key Strategies
  109.     5.2.4 AbbVie Inc. (US)
  110.       5.2.4.1 Financial Overview
  111.       5.2.4.2 Products Offered
  112.       5.2.4.3 Key Developments
  113.       5.2.4.4 SWOT Analysis
  114.       5.2.4.5 Key Strategies
  115.     5.2.5 Eli Lilly and Company (US)
  116.       5.2.5.1 Financial Overview
  117.       5.2.5.2 Products Offered
  118.       5.2.5.3 Key Developments
  119.       5.2.5.4 SWOT Analysis
  120.       5.2.5.5 Key Strategies
  121.     5.2.6 SAGE Therapeutics (US)
  122.       5.2.6.1 Financial Overview
  123.       5.2.6.2 Products Offered
  124.       5.2.6.3 Key Developments
  125.       5.2.6.4 SWOT Analysis
  126.       5.2.6.5 Key Strategies
  127.     5.2.7 HRA Pharma (FR)
  128.       5.2.7.1 Financial Overview
  129.       5.2.7.2 Products Offered
  130.       5.2.7.3 Key Developments
  131.       5.2.7.4 SWOT Analysis
  132.       5.2.7.5 Key Strategies
  133.     5.2.8 Irvine Scientific (US)
  134.       5.2.8.1 Financial Overview
  135.       5.2.8.2 Products Offered
  136.       5.2.8.3 Key Developments
  137.       5.2.8.4 SWOT Analysis
  138.       5.2.8.5 Key Strategies
  139.   5.3 Appendix
  140.     5.3.1 References
  141.     5.3.2 Related Reports
  142. 6 LIST OF FIGURES
  143.   6.1 MARKET SYNOPSIS
  144.   6.2 ITALY MARKET ANALYSIS BY UNDERLYING CAUSE
  145.   6.3 ITALY MARKET ANALYSIS BY DRUG
  146.   6.4 ITALY MARKET ANALYSIS BY PROCEDURES
  147.   6.5 ITALY MARKET ANALYSIS BY END-USER
  148.   6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
  149.   6.7 RESEARCH PROCESS OF MRFR
  150.   6.8 DRO ANALYSIS OF LIFE SCIENCES
  151.   6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
  152.   6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
  153.   6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
  154.   6.12 LIFE SCIENCES, BY UNDERLYING CAUSE, 2024 (% SHARE)
  155.   6.13 LIFE SCIENCES, BY UNDERLYING CAUSE, 2024 TO 2035 (USD Million)
  156.   6.14 LIFE SCIENCES, BY DRUG, 2024 (% SHARE)
  157.   6.15 LIFE SCIENCES, BY DRUG, 2024 TO 2035 (USD Million)
  158.   6.16 LIFE SCIENCES, BY PROCEDURES, 2024 (% SHARE)
  159.   6.17 LIFE SCIENCES, BY PROCEDURES, 2024 TO 2035 (USD Million)
  160.   6.18 LIFE SCIENCES, BY END-USER, 2024 (% SHARE)
  161.   6.19 LIFE SCIENCES, BY END-USER, 2024 TO 2035 (USD Million)
  162.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  163. 7 LIST OF TABLES
  164.   7.1 LIST OF ASSUMPTIONS
  165.     7.1.1
  166.   7.2 Italy MARKET SIZE ESTIMATES; FORECAST
  167.     7.2.1 BY UNDERLYING CAUSE, 2025-2035 (USD Million)
  168.     7.2.2 BY DRUG, 2025-2035 (USD Million)
  169.     7.2.3 BY PROCEDURES, 2025-2035 (USD Million)
  170.     7.2.4 BY END-USER, 2025-2035 (USD Million)
  171.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  172.     7.3.1
  173.   7.4 ACQUISITION/PARTNERSHIP
  174.     7.4.1

Italy Life Sciences Market Segmentation

Life Sciences By Underlying Cause (USD Million, 2025-2035)

  • Male
  • Female

Life Sciences By Drug (USD Million, 2025-2035)

  • Clomiphene Citrate
  • Letrozole
  • Serophene
  • Hormone Treatment
  • Gonadotrophins
  • Aromatase Inhibitors
  • Estrogen Receptor Modulators
  • Dopamine Agonists
  • Metformin Hydrochloride
  • Others

Life Sciences By Procedures (USD Million, 2025-2035)

  • Hysteroscopy
  • Laparoscopy and Robotic Laparoscopy
  • Laparotomy/Open Surgery
  • Egg Retrieval
  • Varicocelectomy
  • Vasectomy Reversal
  • Sperm Retrieval

Life Sciences By End-User (USD Million, 2025-2035)

  • Fertility Clinics
  • Hospitals
  • Clinical Research Institutes
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓